CCK2R Ligand-Linker Conjugates 1 are primarily utilized in targeted cancer therapy. These conjugates are designed to specifically bind to cholecystokinin-2 receptors (CCK2R), which are often overexpressed in certain types of cancer cells, such as medullary thyroid carcinoma and small cell lung cancer. By attaching a therapeutic agent or imaging probe to the ligand, these conjugates enable precise delivery of the payload directly to the cancer cells, minimizing damage to healthy tissues. This targeted approach enhances the efficacy of the treatment while reducing systemic side effects. Additionally, they are explored in diagnostic imaging to visualize tumors and monitor treatment response.